PATENT CLAIM ANALYSIS

Application Number: 15868432
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "172100"]

Abstract:
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

Claim (Index 7):
The method of  claim 5 , wherein the RAR\u03b3 selective agonist that is a compound of general formula (IV) wherein R 1  and R 2  are independently H or C 1-6  alkyl; R 3  is H or F; and X is O, S, CH 2 , C(R 4 ) 2 , or NR 5 , wherein R 4  and R 5  are independently H or C 1-6  alkyl.

Metadata:
- Claim Count in Document: 46.0
- Percentile: 86.0
- Lexical Diversity: 1.16
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15868459', '15868450', '15620411', '15868469', '14507730']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8051621840786111
- 35 USC 102 Novelty (BERT): 0.6238644433688207
- Combined Prediction Score: 0.7870324100076321
- Mean Citation Score: 499.682388
- Max Citation Score: 559.3043
- Similarity Product: 547.2030536619426

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test